MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase

Xu,Weidong; Jiang,Huayong; Zhang,Fuli; Gao,Junmao; Hou,Jun

doi:10.3892/ol.2017.5895

MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase

Authors:
- Weidong Xu
- Huayong Jiang
- Fuli Zhang
- Junmao Gao
- Jun Hou
View Affiliations

Affiliations: Department of Radiation Oncology, The Military General Hospital of Beijing PLA, Beijing 100700, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/ol.2017.5895
Pages: 3387-3394
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the third most common cancer in males and the second most common in females, worldwide. Currently, 5-fluorouracil (5-FU)-mediated chemotherapy is the adjuvant treatment for patients with CRC following surgical resection. However, a number of patients with CRC develop 5‑FU resistance, which is a major challenge for the effective treatment of cancer. Therefore, it is important to investigate the molecular mechanisms underlying chemoresistance and the therapeutic treatments that may improve the treatment of CRC. The present study demonstrated that microRNA (miR)-330 was significantly downregulated in CRC tissues and cell lines. Ectopic miR‑330 expression decreased cell proliferation and enhanced cell chemosensitivity to 5‑FU via the cell apoptosis pathway in CRC. In addition, thymidylate synthase (TYMS) was revealed to be a direct target gene of miR‑330 in CRC. Knockdown of TYMS inhibited CRC cell proliferation, and enhanced cell chemosensitivity to 5‑FU by promoting cell apoptosis. In conclusion, the results of the present study indicated that miR‑330 targeted TYMS to inhibit the proliferation and enhance the chemosensitivity of CRC cells to 5-FU by promoting cell apoptosis. The present study provided important insight into the molecular mechanism underlying 5-FU-mediated chemoresistance and a novel therapeutic strategy for the enhancement of efficacy in CRC treatment.

View Figures

View References

1	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Andrews L: Dietary flavonoids for the prevention of colorectal cancer. Clin J Oncol Nurs. 17:671–672. 2013. View Article : Google Scholar : PubMed/NCBI
4	Altobelli E, Lattanzi A, Paduano R, Varassi G and di Orio F: Colorectal cancer prevention in Europe: Burden of disease and status of screening programs. Prev Med. 62:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
5	Sugarbaker PH: Colorectal cancer: Prevention and management of metastatic disease. Biomed Res Int. 2014:7828902014. View Article : Google Scholar : PubMed/NCBI
6	Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao X, Jia W and Huang J: Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
7	Sun Z, Zhou N, Han Q, Zhao L, Bai C, Chen Y, Zhou J and Zhao RC: MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. Clin Transl Oncol. 17:876–883. 2015. View Article : Google Scholar : PubMed/NCBI
8	Brouquet A and Nordlinger B: Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol. 10:266–267. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kuipers EJ, Rösch T and Bretthauer M: Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol. 10:130–142. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
11	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
12	De Angelis PM, Svendsrud DH, Kravik KL and Stokke T: Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 5:202006. View Article : Google Scholar : PubMed/NCBI
13	Zheng K, Liu W, Liu Y, Jiang C and Qian Q: MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett. 9:869–874. 2015.PubMed/NCBI
14	Yuan W, Sui C, Liu Q, Tang W, An H and Ma J: Up-regulation of microRNA-145 associates with lymph node metastasis in colorectal cancer. PLoS One. 9:e1020172014. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, Ma F and Jiang B: MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 11:232012. View Article : Google Scholar : PubMed/NCBI
16	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
17	O'Hara SP, Mott JL, Splinter PL, Gores GJ and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
19	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
20	Broderick JA and Zamore PD: MicroRNA therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
21	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lu F, Zhang J, Ji M, Li P, Du Y, Wang H, Zang S, Ma D, Sun X and Ji C: miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 45:383–392. 2014.PubMed/NCBI
23	Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, Kobayashi S, Mori M and Doki Y: MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 43:1066–1072. 2013.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Thomas DM and Zalcberg JR: 5-fluorouracil: A pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 25:887–895. 1998. View Article : Google Scholar : PubMed/NCBI
26	Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM and Peters GJ: 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 15:1025–1032. 2004. View Article : Google Scholar : PubMed/NCBI
27	Coget J, Borrini F, Susman S and Sabourin JC: Colorectal carcinomas in 2013: The search for powerful prognostic markers is still on the go! Cancer Biomark. 14:145–150. 2014. View Article : Google Scholar : PubMed/NCBI
28	Li T, Gao F and Zhang XP: miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncol Rep. 33:607–614. 2015.PubMed/NCBI
29	Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY and Gan AH: Colorectal cancer in Guangdong province of China: A demographic and anatomic survey. World J Gastroenterol. 16:960–965. 2010. View Article : Google Scholar : PubMed/NCBI
30	Ades S: Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice. Oncology (Williston Park). 23:162–167. 2009.PubMed/NCBI
31	McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD and Frame MC: Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 67:5248–5257. 2007. View Article : Google Scholar : PubMed/NCBI
32	He Y, Wang J, Wang J, Yung VY, Hsu E, Li A, Kang Q, Ma J, Han Q, Jin P, et al: MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2. Am J Cancer Res. 5:1382–1395. 2015.PubMed/NCBI
33	Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y, Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. Oncol Rep. 30:327–333. 2013.PubMed/NCBI
34	Meng H, Wang K, Chen X, Guan X, Hu L, Xiong G, Li J and Bai Y: MicroRNA-330-3p functions as an oncogene in human esophageal cancer by targeting programmed cell death 4. Am J Cancer Res. 5:1062–1075. 2015.PubMed/NCBI
35	Liu X, Shi H, Liu B, Li J, Liu Y and Yu B: miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 47:431–440. 2015. View Article : Google Scholar : PubMed/NCBI
36	Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z and Liu Y: MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One. 7:e460102012. View Article : Google Scholar : PubMed/NCBI
37	Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and Scheiner J: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 179:663–666. 1957. View Article : Google Scholar : PubMed/NCBI
38	Liu Y, Du F, Zhao Q, Jin J, Ma X and Li H: Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells. Oncol Lett. 9:2675–2679. 2015.PubMed/NCBI
39	Lehman NL: Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs. 11:1775–1787. 2002. View Article : Google Scholar : PubMed/NCBI
40	Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol. 22:529–536. 2004. View Article : Google Scholar : PubMed/NCBI
41	Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res. 4:1243–1250. 1998.PubMed/NCBI
42	Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
43	Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH and Chun HK: Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. Anticancer Res. 31:3843–3849. 2011.PubMed/NCBI